From diagnosis to therapy: how investments are transforming the medical and healthcare industry and strengthening portfolios

How do investments in healthcare help close gaps in care while also generating returns? 

MedTech and healthcare investments are among the most stable and at the same time most innovative segments of the global healthcare market.   

While many markets are subject to strong fluctuations, the demand for medical and healthcare services remains constant. It continues to grow with an aging population, increasing life expectancy  (according to the Deloitte Global Health Care Outlook 2025 the number of people over 65 in Europe will increase by around 30% by 2030) and the rising prevalence of chronic diseases such as diabetes and cardiovascular conditions.  

This demographic shift increases the pressure on healthcare systems and raises demand for efficient, technology-driven solutions.  

At the same time, healthcare systems are reaching their limits: hospitals are struggling with overload, waiting times are increasing, and modern diagnostics are not available to everyone. This is where new business models and medical technologies come into play. They create access where gaps previously existed and improve processes that have so far been inefficient.

For investors, this creates unique opportunities: MedTech and healthcare investments at Invesdor combine social impact with attractive return potential. Investors support concrete solutions with measurable impact.

Through Invesdor, investors gain access to MedTech and healthcare companies that have already overcome key hurdles and are preparing for the next stage of scaling. These projects combine societal impact with financial prospects. They are also aligned with the United Nations Sustainable Development Goals (SDGs).

MedTech & Healthcare Investments at a Glance  

MedTech and healthcare investments involve companies that improve medical care while building on robust business models.

In Europe, more than 90% of the MedTech sector consists of small and medium-sized enterprises (SMEs). This structure opens attractive opportunities for investors to enter early. At the same time, it requires a solid understanding of development stages, as smaller providers are more dependent on regulatory processes and scaling dynamics.

Germany, Switzerland, and the Netherlands are among the world’s most innovative locations.
Many companies here have overcome significant challenges: they are CE-certified, have completed clinical trials, or have generated their first revenue.  

Challenges and opportunities for Europe’s MedTech market   

According to the industry report   MedTech Europe Facts & Figures and MedTech Europe Facts & Figures 2024 the European medical technology market has been growing steadily at around 5% per year for several years. Germany, Switzerland, and the Netherlands are among the most innovation-driven locations worldwide.   
 
Unlike traditional early-stage startups, many companies in this sector have already overcome key challenges: they are CE-certified, have completed clinical trials, or have generated initial revenues.  

For investors, this means they typically enter after this phase while still benefiting from significant scaling potential.

Typical segments include:  

• MedTech: devices, implants, and digital tools for diagnostics and therapy  
• Healthcare infrastructure: for example modern diagnostic systems and equipment fleets that hospitals can use and finance flexibly
• Digital Health:  telemedicine, platforms, and wearables 
  
  

• There are around 38,000 MedTech companies in Europe, about 90% of which are small and medium-sized enterprises (SMEs).
  
• The MedTech sector is one of the most innovative industrial sectors,  accounting for 
  about 8% of all industrial patent applications in Europe. 
  
• MedTech contributes significantly to the economy in terms of employment, exports, and innovation. The European MedTech industry directly employs more than 930,000 people. 
  
• The European MedTech market is estimated at around €170 billion for 2024, representing 
  about 26.4% of the global market. 

(Sources: MedTech Europe Employment & Companies , MedTech Europa Market , MedTech Europe Facts & Figures)  )

Health, innovation, and sustainability: Why Invesdor focuses on MedTech and Healthcare Investments 

These innovation clusters include in particular the Nordic countries. Finland has developed into a leading location for MedTech start-ups. You can learn what enables this success in the article „8 Reasons for the Success of Finnish MedTech Companies“  

Health as a Growth Engine of the European Economy  

The EFPIA report “The Case for Investing in a Healthier Future for the European Union” also shows that every euro invested in the healthcare sector leads to higher quality of life, lower disease costs, and a more resilient economy in the long term. EFPIA concludes that health should be viewed not merely as a cost factor but as a driver of economic growth.

The European MedTech sector is strongly export-oriented. According to MedTech Europe 2024, around 60% of global medical technology exports originate from Europe. For investors, this means stable international demand, currency diversification, and growth beyond national markets.

Sustainability and Regulation Are Becoming More Important 

Invesdor views health as a central pillar of sustainable investments. Medical innovation directly improves the lives of millions of people while creating scalable business models. Every funding request is reviewed before being listed on our platform. The connection to the UN Sustainable Development Goals (SDGs) plays an important role. Depending on the project, the following goals are particularly relevant:

We select projects that meet SDG standards. This ensures that investors support robust business models while contributing to solutions that promote ecological, social, and economic sustainability in healthcare. 

Challenges and Opportunities for Sustainable Investments in MedTech and Healthcare 

The healthcare and MedTech sector is considered one of the most exciting areas for investors—stable, innovative, and with clear societal relevance. At the same time, it is complex: regulations, clinical trials, and technological developments determine the pace and involve elevated risks. Investors should understand these mechanisms and be prepared for longer timelines. With foresight, real and sustainable value can emerge.

New medical technologies take time. From the initial idea through preclinical testing to regulatory approval, several years often pass. During this period, revenues may still be limited while development costs must be financed. For investors, this means such investments are typically medium- to long-term. Once a product reaches the market, its value can increase significantly, particularly after successful CE certification or completed clinical trials.

Many companies on Invesdor are no longer in the highest-risk start-up phase. They have already achieved important milestones such as CE certification, clinical trials, or initial revenues. This allows investors to benefit from a more favorable risk–return profile while gaining access to companies with strong scaling potential.

Developing medical technology products often requires several financing rounds. Each round brings new opportunities but can also lead to dilution. Strategic thinking and potential follow-on investments may therefore be important. Valuations often increase as development progresses, even before significant revenue is generated, creating value through technological advancement.

In healthcare, CE certification is a major milestone. It opens access to the European market and signals that a product meets all safety and quality standards. For investors, this often marks the transition from development to scaling and therefore significant growth potential.

Successful MedTech companies are often acquired by larger corporations or enter partnerships with global players. These exits can generate substantial value increases for investors. The market shows that innovative niche solutions are frequently integrated into international healthcare companies within a relatively short period of time.

When institutional investors or experienced industry investors participate, it sends a strong signal of confidence. They contribute not only capital but also expertise and networks that help companies navigate regulatory hurdles and accelerate growth. For private investors, this provides additional stability and confirmation that the business model is viable.

MedTech and healthcare investments are not designed for short-term speculation but for strategically minded investors who want to combine returns with purpose. Those willing to engage with the development of innovation and pursue long-term goals can benefit both economically and socially.

From Research to Practice: Examples of Successful MedTech Investments

The following examples illustrate different areas of modern MedTech investments. They range from highly specialized diagnostics to digital platform solutions and practical medical aids for everyday life. Each project addresses a clear clinical need, relies on scalable technology, and combines measurable healthcare impact with a sustainable business model. This highlights what matters to investors: evidence-based solutions, transparent milestones, and a clear path to scaling.

Megin: precise brain diagnostics with MEG technology, used worldwide

This is particularly helpful for complex neurological conditions such as epilepsy or brain tumors. More precise diagnostics simplify the planning of surgeries and therapies.

Megin was founded in 1989 and is headquartered in Helsinki. The company is one of the global leaders in MEG technology. More than 120 systems are already installed in hospitals and research institutions. According to the company, it holds over 80% market share in new MEG system installations.

Clinical need and solution: precise mapping of brain function

Neurological diseases often present medicine with a precision challenge. For many procedures, it is crucial to accurately locate specific brain regions. 

Megin’s TRIUX Neo system measures the weak magnetic fields produced by neuronal activity. This allows functional brain areas to be visualized with extremely high temporal and spatial resolution. The method is non-invasive and does not involve radiation exposure. 

This information helps physicians plan procedures more precisely and reduce risks. 

Technology and status: established solution in a specialized market

Megin is considered an established provider in a technically demanding segment of medical technology. Its systems are used worldwide in hospitals and research institutions. Patents, specialized technical expertise, and regulatory requirements create barriers to entry for new competitors. At the same time, demand for precise brain diagnostics is increasing as neurological diseases rise globally.

Impact: better diagnostics and more targeted treatments

When physicians can localize brain functions more precisely, surgeries and therapies can be planned more effectively. This helps reduce risks and improve treatment outcomes. This aligns with the sustainability goal SDG 3 “Good Health and Well-being.” Advances in neurological diagnostics contribute to improving patient care in the long term.

Investor benefit: fixed-interest bond with clear terms

The company was financed through a bond. The terms are clearly structured:  

The financing round reached more than €3.5 million and was supported by more than 1,200 investors.

Megin generates revenue through the sale of MEG systems and service contracts for maintenance and operation. These service contracts provide recurring revenue.

Risks and management: investment cycles and regulatory requirements

The market for highly specialized medical technology is characterized by investment cycles. Hospitals often make large equipment decisions on a long-term and project-based basis. In addition, the installation of an MEG system requires specialized infrastructure such as magnetically shielded rooms. Regulatory requirements and production processes also shape the industry. Megin addresses these challenges through decades of industry experience, an installed system base, and international customer relationships.

Megin illustrates how specialized medical technology can combine investment opportunities with medical progress. Hospitals gain access to precise brain diagnostics while investors participate through a structured bond in the further development of this technology.

 

Pirche: AI-powered platform making organ transplantation more predictable

The need is significant. Many transplanted organs lose function within five to ten years. For patients, this means additional procedures, intensive treatments, and increased health burdens. Any improvement in donor organ matching and post-transplant care can therefore make a meaningful difference.

Clinical need and solution: better matching and more targeted follow-up care 

In transplant medicine, laboratories and medical teams already compare key parameters such as blood type and HLA markers. However, this information is not always sufficient to reliably estimate long-term risks. Pirche expands this analysis with additional immunological models.

The platform creates individualized immune risk profiles and supports clinical decision-making with advanced analyses. It uses data that is already available in many clinical laboratories, allowing the technology to integrate into existing workflows without requiring additional data collection.

Technology and status: patent-protected, scientifically documented, integrated into hospital IT

Pirche combines genetic typing with AI-based analysis to visualize complex interactions between donor and recipient. The underlying algorithms are protected by patents and have been examined in numerous scientific publications.

The platform has already been used in a large number of patient cases and further developed in collaboration with international hospitals and research institutions. Partnerships with laboratory providers such as Thermo Fisher Scientific and Werfen-Immucor facilitate integration into existing hospital IT systems.  

Impact: better treatment outcomes and more efficient resource use

When risks are identified earlier, follow-up care and immunosuppression can be adjusted more precisely. This can help reduce complications and extend the functional lifespan of transplanted organs. Such progress contributes to SDG 3 “Good Health and Well-being.”

Responsible use of medical resources also plays a role. Donor organs are extremely scarce. More precise matching can help extend their usability and avoid repeated procedures.

In addition, the analysis considers specific risk groups in transplant medicine, such as highly sensitized patients. This can help reduce inequalities in healthcare access.

Investor benefit: participation in a scalable B2B SaaS platform

The financing took place through an equity investment (security). The price per share was €15.85, with a minimum investment of 20 shares. Between 1.07% and 5.15% equity was offered at a pre-money valuation of approximately €36.86 million. In total, 578 investors participated.

The business model is based on software-as-a-service contracts with transplant centers and clinical laboratories. Hospitals access the platform through subscriptions, while partnerships with laboratory service providers enable further integration opportunities. Such models can generate recurring revenue when software becomes permanently integrated into clinical workflows.

The investor base includes experienced entrepreneurs and investors from the healthcare industry, including individuals with backgrounds in biotechnology. These investors contribute not only capital but also industry expertise and networks.

Risks and management: clinical adoption, regulation, and market dynamics

Digital diagnostics in clinical practice requires trust, strong evidence, and seamless integration. Pirche addresses these requirements through scientific documentation, a large number of evaluated cases, and IT partnerships. Nevertheless, the speed at which hospitals adopt new decision-support software into processes and budgets remains a key factor.

Regulatory requirements for healthcare software, particularly AI-based systems, also shape development. Pirche focuses strongly on the US transplant market, which offers opportunities but also introduces certain dependencies.

Pirche demonstrates how digital diagnostics can create value in a highly critical medical field. Hospitals gain a platform for improved risk management, patients may benefit from more stable outcomes, and investors participate in a patent-protected B2B SaaS model with documented usage and a clear commercialization strategy.

STIL: Steady Hands for an Independent Life

Since 2023, STIL has been in use—first in the Netherlands and now also in Germany, Belgium, and Italy. Medical supply stores and orthopedic partners fit the orthosis and support users, bringing the solution directly into daily life.

Clinical need and solution: effective, practical, immediately available

Tremors significantly limit everyday life. Eating, writing, or dressing becomes difficult. Shame often leads to social withdrawal.

The STIL orthosis mechanically stabilizes the arm. It dampens uncontrolled movements without restricting natural motion. The effect is immediate. No electricity is required. The orthosis is easy to put on and adjust, even at older ages. Medical supply providers and orthopedic specialists support patients locally.

Technology and status: certification and clinical data

The STIL orthosis is CE-certified and FDA-registered. STIL operates under ISO 13485. A clinical study demonstrates its effectiveness for essential tremor, while additional studies are expanding its application to Parkinson’s disease and other movement disorders. The modular design adapts to different sizes and needs. Distribution partners in the Netherlands, Germany, Belgium, and Italy expand market reach. A new AI-based app supports screening and simplifies initial assessments for patients and distributors.

Impact: more independence, lower costs, stronger participation

Reduced tremors allow people to eat, write, and work independently again. This strengthens dignity and participation. Hospitals and insurers benefit from a non-invasive alternative to surgery or long-term medication. The orthosis helps reduce follow-up costs and relieve healthcare systems. It contributes to SDG 3 and, through durable and repairable product design, also supports SDG 9 (Industry, Innovation and Infrastructure), SDG 10 (Reduced Inequalities), and SDG 12 (Responsible Consumption and Production).

Investor benefit: validated technology, rapid distribution, large market

STIL combines medical benefit with a clear go-to-market strategy. Distribution runs through an established network of medical supply stores and orthopedic partners, including Ottobock (Italy), STOLLE (Germany), and VIGO (Belgium). The addressable market in the EU and the US is worth billions. Renowned investors such as Health Innovations, Rabobank, the EIC Accelerator, and the Brain Foundation Netherlands support growth. The latest valuation was €10 million pre-money. The round offered strengthened shareholder rights for new investors and followed a clear exit logic.

Risks and management: reimbursement, adoption, scaling, regulation

Reimbursement pathways vary by market. STIL works with pilot centers, key opinion leaders, and partners to secure coverage. Adoption in daily practice is supported by training, simple fitting processes, and distributor support. Scaling and supply chains are planned step by step with clear quality processes. CE certification, FDA registration, and ongoing studies reduce regulatory uncertainty. The AI screening app improves matching and increases success rates in patient care.

STIL brings a clinically validated, non-invasive solution into standard care. Patients gain independence in daily life. Healthcare providers operate more efficiently. Investors gain access to a scalable MedTech company with a clear distribution strategy, growing partnerships, and strong validation.

 

Healthcare investments: benefits for people and investors

Investments in MedTech and healthcare combine economic stability with social impact. They allow investors to actively contribute to improving medical care while achieving attractive long-term returns.

MedTech and healthcare projects are a valuable addition to a diversified portfolio. They respond to global megatrends such as demographic change, technological innovation, and the growing demand for efficient healthcare.

For Invesdor, it makes sense to focus on companies that:

develop new medical technologies that improve diagnostics, therapy, or care,
optimize existing systems by digitizing processes or making devices more sustainable, 
expand medical infrastructure, for example through pay-per-use models or mobile solutions,  
scale internationally to bring innovations to new markets more quickly.  

Such projects meet clear sustainability and quality standards and offer strong value creation potential.

The healthcare sector is considered particularly resilient: people require medical services regardless of economic cycles. Healthcare investments therefore offer long-term stability. Companies with CE certifications and validated clinical data increasingly meet strict regulatory requirements, which further strengthens their market position.

A structured due diligence process such as the one applied by Invesdor helps reduce these risks.

Projects are evaluated based on financial metrics, clinical evidence, ESG criteria, and sustainability standards. This provides investors with access to vetted, viable, and impact-oriented companies.

An investment in the healthcare sector allows investors to influence the future of medical care. Those who invest in MedTech and healthcare contribute to accelerating innovation, improving patient access to treatment, and strengthening healthcare systems worldwide—while combining this social contribution with a clear economic perspective.

Invest in health now: your chance to actively shape the future! 

Healthcare and MedTech investments combine financial stability with social impact. Investors support innovations that improve lives—from advanced diagnostics and digital health solutions to new medical technologies. At the same time, they benefit from a growth market that is largely independent of economic cycles.

Those who invest in this sector promote progress, improve access to better care, and actively shape the future of medicine.

Discover current investment opportunities on Invesdor:
projects that combine medical progress with economic potential.

Start today and invest in a healthier future!